Potential opportunity size greater than PKD in B* unrisked modellingPYC’s renal program in Polycystic kidney disease (PKD) supports ~50% of PT today, but when looking at our unrisked valuation ($18/sh assuming 100% probability of success for all programs) PMS reflects a greater opportunity vs PKD (B*e $3.5b EV vs $3.1b EV respectively).
—//—
Barrenjoey’s Mellisa Benson is suggesting this new drug could actually prove to be bigger than PCKD
PYC seem to now have 2 blockbuster opportunities in their pipeline
Ann: Fourth Drug Program Progressing to Human Trials, page-4
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$1.38 |
Change
-0.015(1.08%) |
Mkt cap ! $804.8M | |||
| Open | High | Low | Value | Volume |
| $1.39 | $1.43 | $1.37 | $120.6K | 86.38K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 3808 | $1.38 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.40 | 2467 | 2 |
View Market Depth
| Last trade - 14.39pm 15/07/2025 (20 minute delay) ? |
| PYC (ASX) Chart |